Research and Markets: Global Chemotherapy Induced Peripheral Neuropathy Pipeline Review, H2 2015 - 12 Companies & 17 Drug Profiles

Research and Markets (http://www.researchandmarkets.com/research/r5lb5x/chemotherapy) has announced the addition of the "Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Peripheral Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Peripheral Neuropathy and special features on late-stage and discontinued projects

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

• DARA BioSciences, Inc.
• DermaXon, LLC
• Eisai Co., Ltd.
• Immune Pharmaceuticals Inc.
• Laboratorios Del Dr. Esteve S.A.
• MAKScientific, LLC
• Mertiva AB
• Panacea Pharmaceuticals, Inc.
• PharmatrophiX, Inc.
• Spectrum Pharmaceuticals, Inc.
• Spinifex Pharmaceuticals Pty Limited
• Virobay Inc.

Drug Profiles

• (amitriptyline + ketamine hydrochloride)
• AL-309
• AM-1710
• Drug for Pain
• DX-0332
• E-2072
• E-52862
• EMA-401
• Gene Therapy for Chemotherapy Induced Peripheral Neuropathy
• ketoprofen
• KRN-5500
• LM11A-31
• PAN-811
• PGN-703
• Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis
• SPI-205
• VBY-036

For more information visit http://www.researchandmarkets.com/research/r5lb5x/chemotherapy

View source version on businesswire.com: http://www.businesswire.com/news/home/20151126005437/en/